TSL2109

Overview

TSL2109 is an orally active and selective DYRK2 and CDK4/6 inhibitor with an IC 50 value of 22 nM for DYRK2 . TSL2109 exhibits high kinase selectivity over 93%. TSL2109 arrests cell cycle and induces apoptosis in virto. TSL2109 effectively overcomes Enzalutamide ( HY-70002 ) resistance by suppressing tumor growth in vivo and virto. TSL2109 also shows CDK4/6 inhibitor resistance.TSL2109 demonstrates safety profile. TSL2109 can be used for prostate cancer research and breast cancer [1][2] .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer | Products > Signaling Pathways > DYRK

Product Information

• Catalog No.: HY-180574
• CAS No.: 2619847-12-8
• Molecular Formula: C28H33FN8OS
• Molecular Weight: 548.68
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source